M
Mohamed A. Ismail
Researcher at Hamad Medical Corporation
Publications - 11
Citations - 99
Mohamed A. Ismail is an academic researcher from Hamad Medical Corporation. The author has contributed to research in topics: Medicine & Myeloid leukemia. The author has an hindex of 4, co-authored 7 publications receiving 68 citations. Previous affiliations of Mohamed A. Ismail include Kingston University.
Papers
More filters
Journal ArticleDOI
A new monoclonal antibody detects downregulation of protein tyrosine phosphatase receptor type γ in chronic myeloid leukemia patients
Marzia Vezzalini,Andrea Mafficini,Luisa Tomasello,Luisa Tomasello,Erika Lorenzetto,Elisabetta Moratti,Zeno Fiorini,Tessa L. Holyoake,Francesca Pellicano,Mauro Krampera,Cristina Tecchio,Mohamed A. Yassin,Nader Al-Dewik,Mohamed A. Ismail,Ali Al Sayab,Maria Monne,Claudio Sorio +16 more
TL;DR: A newly developed murine monoclonal antibody specific for the PTPRG extracellular domain is characterized and exploited to better definePTPRG protein downregulation in CML patients and permits its evaluation for clinical application including the support for diagnosis and follow-up of these disorders.
Journal ArticleDOI
Is Adherence to Imatinib Mesylate Treatment among Patients with Chronic Myeloid Leukemia Associated with Better Clinical Outcomes in Qatar
Nader Al-Dewik,Hisham Morsi,Muthanna Samara,Rola Ghasoub,Cinquea C. Gnanam,Subi K. Bhaskaran,Abdulqadir J. Nashwan,Rana Al-Jurf,Mohamed A. Ismail,Mohammed Alsharshani,Ali A. AlSayab,Tawfeg Ben-Omran,Rani Khatib,Mohamed A. Yassin +13 more
TL;DR: The preliminary results show that patients�’ response to treatment may be directly linked to patients’ adherence to treatment, and efforts should be made locally to improve access to medication for cancer diseases.
Journal ArticleDOI
CD49d and CD26 are independent prognostic markers for disease progression in patients with chronic lymphocytic leukemia.
TL;DR: CD49d and CD26 have independent prognostic value and its use as a part of routine panel for prognostic stratification of CLL is suggested and it is suggested to improve their predictive power.
Journal ArticleDOI
Aberrant DNA methylation of PTPRG as one possible mechanism of its under-expression in CML patients in the state of Qatar
Mohamed A. Ismail,Mohamed A. Ismail,Muthanna Samara,Ali Al Sayab,Mohamed Alsharshani,Mohamed A. Yassin,Govindarajulu Varadharaj,Marzia Vezzalini,Luisa Tomasello,Maria Monne,Hisham Morsi,M. Walid Qoronfleh,Hatem Zayed,Richard T. Cook,Claudio Sorio,Helmout Modjtahedi,Nader Al-Dewik +16 more
TL;DR: Protein tyrosine phosphatase receptor gamma expression is a natural inhibitory mechanism that is downregulated in chronic myeloid leukemia (CML) disease and the mechanism behind its downregulation has not been fully elucidated yet.
Journal ArticleDOI
Incidence, Risk Factors, and Outcomes of Preterm and Early Term Births: A Population-Based Register Study
Salma Younes,Muthanna Samara,Rana Al-Jurf,Gheyath K. Nasrallah,Sawsan Al-Obaidly,Husam Salama,Tawa Olukade,Sara Hammuda,Mohamed A. Ismail,Ghassan Abdoh,Palli Valapila Abdulrouf,Tom Farrell,Mai AlQubaisi,Hilal Al Rifai,Nader Al-Dewik +14 more
TL;DR: In this article, the authors examined 15,865 singleton live births using 12-month retrospective registry data from the PEARL-Peristat Study and found that all groups of PTB and ETB were significantly associated with low birth weight (LBW), large for gestational age (LGA) births, caesarean delivery, and neonatal intensive care unit (NICU)/or death of neonate in labor room (LR)/operation theatre (OT).